Targeted therapy is the first choice for the treatment of NSCLC patients with MET exon 14 skipping mutation, including multi-targeted drugs (crizotinib, cabozantinib) and selective targeted drugs (savolitinib, capmatinib, teponitinib). Here, MET is linked to non-small cell lung carcinoma.